These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28318106)

  • 1. Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
    Gessoni G; Valverde S; Valle L; Gessoni F; Caruso P; Valle R
    Int J Lab Hematol; 2017 Aug; 39(4):418-422. PubMed ID: 28318106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
    Gessoni G; Valverde S; Gessoni F; Valle R
    Blood Transfus; 2015 Oct; 13(4):666-8. PubMed ID: 25761318
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
    Gessoni G; Valverde S; Valle L; Caruso P; Gessoni F; Valle R
    Blood Transfus; 2017 Oct; 15(6):562-567. PubMed ID: 28287382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
    Maryamchik E; Rosenbaum MW; Van Cott EM
    Arch Pathol Lab Med; 2018 Jan; 142(1):70-74. PubMed ID: 28920711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods.
    Maryamchik E; Van Cott EM
    Arch Pathol Lab Med; 2020 Nov; 144(11):1401-1407. PubMed ID: 32101451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, together with 1982_1983del).
    Shimonishi N; Morishita E; Ogiwara K; Maruyama K; Yoshida J; Horie K; Nogami K
    J Thromb Haemost; 2024 Oct; 22(10):2810-2822. PubMed ID: 38950780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
    Delahousse B; Iochmann S; Pouplard C; Fimbel B; Charbonnier B; Gruel Y
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):503-9. PubMed ID: 9491268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
    Reuner KH; Litfin F; Patscheke H
    Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):41-5. PubMed ID: 9156566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
    Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
    Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
    Castaman G; Tosetto A; Ruggeri M; Rodeghiero F
    Br J Haematol; 1999 Jul; 106(1):232-6. PubMed ID: 10444192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
    Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
    Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limitations of a calibrated, quantitative APC-R assay under routine conditions.
    Jilma-Stohlawetz P; Lysy K; Sunder-Plassmann R; Belik S; Jilma B; Pabinger I; Quehenberger P
    Int J Lab Hematol; 2021 Apr; 43(2):318-323. PubMed ID: 33131213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
    Guerrero F; Arnaud C; Nguyen F; Boneu B; Sié P
    Thromb Haemost; 2006 Apr; 95(4):728-34. PubMed ID: 16601846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
    Baig MA
    Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
    Sayinalp N; Haznedaroğlu IC; Aksu S; Büyükaşik Y; Göker H; Parlak H; Ozcebe OI; Kirazli S; Dündar SV; Gürgey A
    Clin Appl Thromb Hemost; 2004 Jul; 10(3):265-70. PubMed ID: 15247984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
    Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
    Sedano-Balbás S; Lyons M; Cleary B; Murray M; Gaffney G; Maher M
    BMC Pregnancy Childbirth; 2010 Mar; 10():11. PubMed ID: 20214832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
    Ivey LM; Thom JY; Ivey JG; Baker RI
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.